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Abstract. Nancy Flournoy was born in Long Beach, California, on
May 4, 1947. After graduating from Polytechnic School in Pasadena in
1965, she earned a B.S. (1969) and M.S. (1971) in biostatistics from
UCLA. Between her bachelors and masters degrees, she worked as a
Statistician I for Regional Medical Programs at UCLA. After receiving
her master’s degree, she spend three years at the Southwest Laboratory
for Education Research and Development in Seal Beach, California.
Flournoy joined the Seattle team pioneering bone marrow transplan-
tation in 1973. She moved with the transplant team into the newly
formed Fred Hutchinson Cancer Research Center in 1975 as Director
of Clinical Statistics, where she supervised a group responsible for the
design and analysis of about 80 simultaneous clinical trials. To support
the Clinical Division, she supervised the development of an interdisci-
plinary shared data software system. She recruited Leonard B. Hearne
to create this database management system in 1975 (and married him
in 1978). While at the Cancer Center, she was also at the University
of Washington, where she received her doctorate in biomathematics in
1982. She became the first female director of the program in statistics at
the National Science Foundation (NSF) in 1986. She received service
awards from the NSF in 1988 and the National Institute of Statisti-
cal Science in 2006 for facilitating interdisciplinary research. Flournoy
joined the Department of Mathematics and Statistics at American Uni-
versity in 1988. She moved as department chair to the University of
Missouri in 2002, where she became Curators’ Distinguished Professor
in 2012.
While at the Cancer Center, Flournoy documented the graft-versus-
leukemia effect in humans and discovered a source of frequent lethal
viral infections in the bone marrow transplant patients. Later she was
influential in developing adaptive experimental designs. Her numerous
honors include fellow of the Institute of Mathematical Statistics (1990),
the American Statistical Association (1992), the World Academy of
Arts and Sciences (1992) and the American Academy for the Advance-
ment of Science (1993). She has received the COPSS Scott (2000) and
David (2007) awards, and the Norwood (2012) award from the Univer-
sity of Alabama.
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Fig. 1. Nancy at home in a part of Los Angeles County that
was then called Potero Heights, 1949.
1. EARLY LIFE
Rosenberger: Tell us a little about your early life.
Where did you grow up and what did your parents
do?
Flournoy: I was born in Long Beach, CA, and grew
up in Los Angeles County in a lemon orchard sur-
rounded by oil wells and a flood plain. There was a
dairy farm nearby and we had a donkey. My father
was a plumbing contractor who plumbed Los An-
geles: restaurants, dormitories, cemeteries. He had
11 trucks go out every day. My Mom was always
unhappy about not finishing college, so she enrolled
in college when I went to college and then directed
a preschool for many years. I have three brothers
and one sister. I was sent to Polytechnic School in
Pasadena as a sophomore in high school. On the en-
trance exam I had the second highest score in math
in history, but I flunked the English exam because I
didn’t know the words in the instructions. (So even
then I had a one-sided brain!)
Rosenberger: As a young person, were you inter-
ested in mathematics, statistics, data? What made
you excited about statistics?
Flournoy: High school algebra really made me
happy; I would lay on the floor and work problems
for hours. I had a new female instructor whose hus-
band had gotten a professorship across the street at
Fig. 2. Nancy at her graduation from Polytechnic School,
Pasadena, 1965.
Cal Tech while she just landed a high school job;
her anger came through and I got the message that
mathematics is worth being passionate about.
My love of statistics came as a junior at UCLA,
when I took a course taught by Don Ylvisaker. I just
assumed that Don was a great teacher for all time,
but he later told me that he never had another class
like it. Four or five students from that class went on
to get doctorates in statistics.
Rosenberger: You were fortunate to be at UCLA
at a time when there were some of the great names in
biostatistics: Abdelmonen Afifi, Frank Massey, Wil
Dixon, Olive Dunn, Virginia Clark. What professors
excited you at UCLA?
Flournoy: Afifi was the young dynamic professor
and taught out of Scheffe´; all the students loved
Afifi. Dixon had a bimodal distribution among the
students; you either loved him or hated him. He put
out a thousand ideas a minute; if you paid close at-
tention, you would find they were pearls. It was a
challenge to get what he was saying as he didn’t
change the tone of his voice when he switched from
one topic to another. He taught the power of data
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analysis as a tool for learning and a thousand lit-
tle ways to make the data sing. I had a class with
Frank Massey; I learned a lot, but he was quiet and
not dynamic.
Rosenberger: Did you have any connection to the
Department of Statistics? You mentioned Ylvisaker.
What about Paul Hoel?
Flournoy: A separate statistics department did
not exist at that time; it was a math department
with a few statisticians. I used the Hoel, Port and
Stone probability book when it was just a set of
notes. I don’t think Hoel was the instructor though.
Rosenberger: What interested you in biostatis-
tics?
Flournoy: Most of the statistics courses that were
offered at UCLA were in the Department of Bio-
statistics. Prior to taking statistics, I had loved bio-
chemistry and was a nutrition major, leading to my
major in the School of Public Health (SPA). When
I recognized that with a degree in nutrition, I would
probably only be able to run a cafeteria in a hos-
pital, I decided to get my degree in mathematics
instead. I applied repeatedly to change from SPA to
the College of Arts and Sciences (CAS), but my ap-
plication would get turned down. In tears, I didn’t
know what to do. Then the SPA Dean asked why
I was flunking out, which didn’t make sense since
I always had gotten As and Bs. They had lost all
my records because I had changed names when I
was previously married, and nothing followed me.
So that’s why they didn’t accept me at CAS. By
the time this got settled, I had enough credits to
get a degree in biostatistics.
2. GRADUATE SCHOOL
Rosenberger: What did you do after you gradu-
ated? How did you get to graduate school?
Flournoy: When I got a job at Regional Medi-
cal Programs as a Statistician I, one old man would
come around and ask me to add numbers; I told him
he could hire a statistical clerk for half my salary.
I was told that, as a young woman, my presenta-
tions were not credible. So they hired a male DrPh
to present my reports in his name. As a mild way
of protesting, I put my hair in a bun, dyed it white,
and got fired. They said I was an “uppity woman.”
At that time, Virginia Clark was department chair.
She said, “We have a fellowship, why don’t you come
to grad school?” I have some happy memories of my
master’s program at UCLA: Olive Dunn supervised
my master’s thesis; Mary Ann Hill was a great teach-
ing assistant for Dixon’s class; Carol Newton taught
a mean FORTRAN programming course; and Ray
and Jean Mickey were influential in my career deci-
sions.
Fig. 3. Nancy with her parents, Elizabeth Blincoe and Carr Irvine Flournoy, at her graduation from the University of
Washington in 1982.
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Rosenberger: When you won the David Award,
you talked about meeting F. N. David. Tell us about
that.
Flournoy: I was in the Los Angeles chapter of the
ASA; around 1972, a group of us carpooled out to
UC Riverside where David was giving a talk. She
had a strong presence, standing with one leg up on
a stairstep and smoking a cigar while she talked.
It was a roomful of people, and she exuded such
confidence. So I immediately started smoking cigars.
I had been used to seeing female statisticians such as
Clark and Dunn behind a desk and not commanding
an audience.
Rosenberger: How did you get to University of
Washington (UW)?
Flournoy: After the M.S., I thought I knew every-
thing about statistics. I got a job at Southwest Ed-
ucation and Laboratory for Research, where there
were a lot of education psychologists who were into
experimental design. On my second day, they pre-
sented me with computer output that had more than
one error term; I had the good sense to keep my
mouth shut. I immediately called Wil Dixon and
asked what they were talking about. He replied, “Oh
well, we can’t teach you everything.” He suggested
I get a book by Walt Federer. The book was out of
print, but Walt got a preprint from India and sent it
to me; so I spent my nights reading Federer’s book.
Later, I was trying to read the Journal of the
American Statistical Association to implement some
of the stuff I wanted to do, and I found I couldn’t
read the literature. I also wanted to escape the smog
of Los Angeles. So I applied to the UW, my only
application. Dick Kronmal said there was a research
assistant position with the bone marrow transplant
team, which was then located in the Old Public Hos-
pital (recently Amazon) in Seattle.
At that time, there was no statistics department
at UW. The mathematical statistics courses were
taught in the Department of Mathematics. I took
the mathematical statistics sequence from Galen
Shorack. I had courses from Ron Pyke and Fritz
Schultz in nonparametrics. Shortly after Fritz left
for Boeing, the remaining statistics faculty formed
the Department of Statistics. In the Department of
Biostatistics, there were some female faculty: Paula
Diehr and Pat Wahl. I took the first categorical data
analysis class taught at UW from Norman Breslow.
He gave quizzes at the end of class, so I never paid
so much attention in a course before. I took survival
from Ross Prentice early in the days of the Cox pro-
portional hazards model.
Rosenberger: What was it like working with your
dissertation advisor, Lloyd Fisher?
Flournoy: It worked out well because we have sim-
ilar work styles. Both of us had busy consulting lives;
we would schedule meetings and get our business
done.
3. THE SEATTLE BONE MARROW
TRANSPLANTATION TEAM
Rosenberger: Today every street corner seems to
have a contract research organization for data co-
ordinating centers on large clinical trials. But when
you went to the Fred Hutchinson Cancer Research
Center, information technology was primitive, such
places did not exist. You had to create that envi-
ronment on your own. What was it like? What were
the challenges?
Flournoy: That’s an interesting story. Dick Kron-
mal had invested a lot of effort in creating a database
management system without requiring a rectangular
data structure. Updates required physically sorting
the cards (remember all data records had to fit into
the 80 digits of a Hollerith punch card—so I tend to
use the words “card” and “record” interchangeably).
There was a transplant data set in place with seven
different kinds of cards. Kronmal had E. Donnal
“Don” Thomas (Director of the Clinical Research
Division at the Cancer Center) buy a computer. The
computer weighed 50 pounds (I could toss it in my
van and take it home; the cost was about $50,000),
and data storage was on Phillips cassette tapes.
Records could be transmitted across the phone wires
and then integrated into the database at UW. Ini-
tially, there was not much data (only 10 patients)
and the first update took my whole computing bud-
get for the year! What I did then for some period of
time was, when it was time to do an update, punch
cards of the whole database and the new dataset; I
would physically sort and merge the cards by hand
and load them into SPSS. That was my “dirty laun-
dry” story because the laundromat had big long ta-
bles and I sorted cards while doing laundry. Kronmal
told me that, if I had any trouble with my new com-
puter, I should call Leonard Hearne. Index sequen-
tial files were brand new at that time, and Leonard
used them to create an early database management
system before the word was in the literature (see
Flournoy and Hearne, 1981, 1990a, 1990b). We used
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it for several years until a commercial system came
on the market. At site visits, someone would ask a
question and I would pass a note down to a program-
mer, who would extract the answer in 15 minutes or
so. We set the bar for oncology programs.
Ross Prentice came from the University of Wa-
terloo with a box of cards on the Cox proportional
hazards model; we were really early using that. The
doctors were smart enough to understand the limi-
tations in using discriminant analysis and they were
thrilled to be able to incorporate censored survival
data in their regression models. My work document-
ing graft vs. leukemia in humans was very impor-
tant (see Weiden et al., 1979, 1981a, 1981b, 1981c).
One hypothesis motivating the development of bone
marrow transplantation was that the marrow graft
would attack residual leukemia also. Immunological
activity of the graft was apparent when the graft
instigated an immunological attack on the patient.
I modeled the impact of this attack on the relapse
rate. The protection of the graft attack against re-
lapse greatly complicated post-transplant treatment
strategies. But our findings have withstood the test
of time. It was, perhaps, the first major applica-
tion of the proportional hazards model with time-
dependent covariates.
Rosenberger:When you think of the success of the
bone marrow transplant program (Don Thomas won
the Nobel prize in 1990 for developing bone marrow
transplantation as a treatment for leukemia), how
much did statistics and data management play a
role in that? Do you think statistics and data man-
agement will ever get its due?
Flournoy: We had this rudimentary set of records
that could be added onto infinitely. It started out
that bacteriology wanted to add a card, then vi-
rology, then specific studies would add a card with
their data. Before you knew it, we had an inter-
disciplinary shared database with assigned patient
numbers so all the integrated data was available.
I was able to say “do you know what they’re do-
ing in virology that’s related” because I knew ev-
erybody’s data. It wasn’t until many years later
that people started talking about having integrated
shared databases. Most were established for billing
purposes, not for research purposes. They are differ-
ent constructs. Hospitals would archive data after
the bill was paid but we wanted to keep it around
forever.
When the program started, there was one of ev-
erybody (one statistician, one virologist, etc.), and
we would sit around the table and share results. It
was important to be influential and to catch prob-
lems in data collection and quality control before
they got big. When working with new doctors, there
were humps you had to get over because they would
claim that there were no quality control issues: their
lab people never made a mistake. A lot of negotia-
tion had to go on before we could agree. Yes, we had
a huge influence. Even randomization and blinding
was controversial. If it was in the middle of the night
the cards might get shuffled; there was too much
room for bias. We introduced them to a very careful
Fig. 4. Yash Mittal, first female director of the probability program, and Nancy, first female director of the statistics program,
at NSF.
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randomization regimen for treatment assignments,
with a 24 hour on-call person.
It will be hard for statistics and data manage-
ment to ever get its full due because the doctors
are so enamored of themselves (laughs). It’s really a
strange system where the people with the least sci-
ence background usually run the science. Also, the
data management budget was always the first to be
cut; yet it is very expensive to do a quality job.
Rosenberger:What has your role been in fostering
interdisciplinary research?
Flournoy: Having conducted interdisciplinary re-
search for more than a decade at the Cancer Center,
I knew the power that teams of interdisciplinary
researchers could bring to bear on important sci-
entific questions. Coincidentally, when I went to
the National Science Foundation (NSF) in 1986,
the Division of Mathematical Sciences (DMS) had
funded the Institute of Mathematical Statistics
(IMS) to write a report on cross-disciplinary re-
search. I watched the growth in their thinking as
they interacted with each other. At the time, the
discipline did not appreciate the role of applications
in academic settings. I think I was able to influ-
ence the IMS cross disciplinary committee on the
valuable nature of interdisciplinary work. The re-
port of the committee had a dramatic effect on the
discipline. The report proposed establishing the Na-
tional Institute of Statistical Science. Since I was at
NSF, I was able to promote the idea of establishing
a broad institute that would work on problems of
national importance.
At the same time, I would receive proposals from
statisticians motivated by applications. Because our
budget was small, I took such proposals around to
the relevant disciplines that were involved, and was
able to get some joint funding. This resulted in my
getting an award in 1988 for facilitating the fund-
ing of these interdisciplinary projects. This also led
to specific DMS requests for proposals for interdis-
ciplinary research projects, which are now common
throughout NSF.
4. ADAPTIVE DESIGNS
Rosenberger: How did you get interested in adap-
tive designs?
Flournoy: While at the Cancer Center, the major
program project grant had five-year reviews. When
we prepared for the third one of these, we spent a
year reviewing what we had done and how we would
go forward. In the course of that retrospective, I
developed some feelings about the two arm clinical
trial. The standard ideas about the two arm clini-
cal trials came from the Peto paper in the mid 70s
(Peto et al., 1976, 1977). But, in my experience, a
treatment is a point in a high dimensional space: in-
volving drugs, radiation, including how much, how
often; and one learned little about this high dimen-
sional space using the traditional two arm clinical
trial. For instance, we spent five years comparing
A to B; but then we go back to the high dimen-
sional space and pick out point C, and have another
five years of experimentation and compare A to C.
Then we compare C to D, and after 15 years we
have knowledge of four points in a high dimensional
space. I believed it would be more efficient and in-
formative to know which direction we should head
in the high dimensional space. So that led me to
think about adaptive designs. I recommended sev-
eral to the group and the physicians liked the ideas,
but thought they may be too radical to get funded.
Another thing that promoted my interest was
looking at pilot studies to decide what to take for-
ward to larger studies. Bob Tsutukawa was visiting
the Cancer Center from the University of Missouri
at the time. I thought his Bayesian ideas were ap-
pealing and I used expert opinion for prior elicita-
tion (see Flournoy, 1993). The prior was way off, so
we wound up with a lot of toxicities. You just can’t
trust the best expert opinion of the best experts,
and so there needed to be some way to use interim
data faster to adapt and put much less weight on
the prior. My later work showed how random walk
rules could be constructed to do this (see Durham
and Flournoy, 1994; Durham, Flournoy and Rosen-
berger, 1997; Flournoy and Oron, 2015).
Rosenberger: The first time I heard the name
Nancy Flournoy was in the context of the 1989 ses-
sion on adaptive designs at Joint Statistical Meet-
ings (JSM) in Washington. It turned out to be one
of the most controversial sessions in the history of
JSM. Talk about that.
Flournoy: My experience at NSF was that you
don’t make progress without community. One per-
son alone doesn’t get much done. So I had the idea
that a JSM session on adaptive design would bring
together people who are interested in adaptive de-
signs. I didn’t know anyone personally. I invited
based on my impressions of their interests. I in-
vited Don Berry, Richard Simon and Janis Hard-
wick. I gave a straightforward technical talk on the
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Fig. 5. 1994 IMS Workshop on Sequential Analysis at University of North Carolina, Chapel Hill. Included are Nancy
Flournoy (seated second from left), Lynne Billard (immediately behind Nancy), Janis Hardwick (to the right of Lynne), Bill
Rosenberger (third row from back, middle), and Steve Durham (directly in front of right window).
topic. The remainder of the session focused primar-
ily on criticism of the extracorporeal membrane oxy-
genation (ECMO) trials (e.g., Barlett et al., 1985;
O’Rourke et al., 1989; Ware, 1989). (The ECMO
trial was an implementation of the randomized play-
the-winner rule of Wei and Durham, 1978, in which
11 babies were assigned to an experimental arm, and
all survived, while one baby assigned to the conven-
tional arm, died. The historical death rate on the
conventional arm was 80 percent.) To my dismay,
all the negative focus of the session was directed to-
ward the adaptive design aspect of the clinical trial,
rather than on the sample size and what kind of
sample size would be needed for the trial to be con-
vincing. The press that was generated by this session
set adaptive designs back a long time.
Rosenberger: How much do you think the failed
ECMO trial inhibited the development of adaptive
designs?
Flournoy:What would have been a reasonable ap-
proach? The original trial was unconvincing due to
having few patients, in spite of the fact that a prob-
abilistically reasonable stopping rule was applied.
The controversy over the subsequent two arm trial in
clinical research set back adaptive designs wrongly.
The adaptive trial was so successful that only one
baby died; is that bad?
Rosenberger: In your 1992 AMS/IMS/SIAM con-
ference on adaptive designs (Flournoy and Rosen-
berger, 1995), you brought together some of the
groundbreakers of adaptive designs along with a
number of younger faculty who are now at the fore-
front of the discipline. At the opening session, you
started by talking about the need to streamline the
process of clinical trials, the end to phases and the
incorporation of dynamic interim decisions. You said
that will revolutionize the way we do clinical tri-
als, and that this conference would be an ambi-
tious beginning to that revolution. Now, over two
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decades later, there are 70-some sessions on adap-
tive designs at the Joint Statistical Meetings, “big-
pharma” working groups, Food and Drug Adminis-
tration white papers and guidelines, companies like
ADDPLAN, and CYTEL devoted to adaptive de-
sign software and everyone wants to do adaptive de-
signs. What took so long?
Flournoy: ECMO made a steep hole to climb. We
also had to develop theory. It was one thing to say
“this is a good idea,” and another to adequately
support it. Some ideas were NOT good. This in-
cludes a class of procedures that derive from stochas-
tic approximation, that Val Fedorov coined “best
intention” designs. In these designs, a target dose
is estimated (such as the dose having a particular
percent toxicity or one that maximizes some utility
function); then that estimate is the dose given to
the next subject. Some, including Lai and Robbins
(1982), understood early on that using this proce-
dure without safeguards may result in treatment se-
quences that converge to the wrong dose. But others,
including myself (Li, Durham and Flournoy, 1995),
were enamored of this idea and ignorant of ear-
lier warnings. This approach remains popular today
even as recent publications are exposing just how
misleading it can be (e.g., Azriel, 2012, Oron and
Hoff, 2013).
In the 1980s, JohnWhitehead spent a year visiting
the Cancer Center from the University of Reading,
and promoted the idea of using sequential stopping
rules taking censoring into account. Its value was so
obvious that I expected that by 1990 every clinical
trial would be using these techniques. So I focused
instead on adaptive allocation. At American Uni-
versity (AU), I worked on theoretical problems in
these areas. When I pulled my head out and looked
around I was shocked to see that stopping rules in-
corporating censoring were not being used, except a
bit in cancer. So things that seem obvious to some
can take a long time to enter the medical arena.
Take the “3+3” dose escalation design as an exam-
ple. It has been soundly discredited (Reiner, Pao-
letti and O’Quigley, 1999; Lin and Shih, 2001), and
yet remains a standard practice in oncology phase I
trials.
Adaptive allocation is still in its infancy compared
to sequential monitoring and stopping. Now there
has developed a new belief that simulation is ad-
equate for assessing an adaptive design. But rely-
ing solely on simulation muddies the water because
there is no global view of what is driving the design.
In addition, there are many papers in the literature
that report only averages over simulations without
measures of variability. When you consider measures
of variability, a completely different picture emerges
(Oron and Hoff, 2013). I fervently believe in devel-
oping the theory underlying classes of designs. For-
tunately, many people are interested in working on
the theoretical challenges, and there are a lot of in-
teresting open questions.
Rosenberger: Many times when I hear talks on
adaptive designs I want to scream out “Nancy
Flournoy thought of that in the 1980s.” How do you
feel about some of your early ideas being ignored?
Flournoy: Well, I’m hardly alone in this. For in-
stance, Chris Jennison invented many clever tech-
niques for sequential and adaptive clinical trials
very early that are sometimes “rediscovered” with-
out reference (e.g., Jennison, Johnstone and Turn-
bull, 1982; Kulkarni and Jennison, 1986; Jennison,
1987). In my case, it amazes me that there are a
large number of people who will reference a paper
from the 1980s and ignore 30 years of my research.
For example, the early up and down paper of Storer
(1989) is often cited without reference to my later
papers that have much more sophisticated control
of the adaptive process. This early paper is used as
a whipping post to declare up and down procedures
inferior. An up and down design is a random walk
that can end anywhere. The last state (dose) vis-
ited should not be used as an estimator. But this
is done when the up and down design is compared
to other procedures that derive from stochastic ap-
proximation (e.g., Zacks, 2009). That bothers me a
lot.
Rosenberger: How did you meet Steve Durham?
This began one of the great collaborations in statis-
tics. Tell us about that.
Flournoy: One of the few positive consequences of
the 1989 JSM session was meeting Steve Durham
from the University of South Carolina. When I
walked out the door after the session, Steve intro-
duced himself and was very excited because we were
basically working on the same mathematical prob-
lems, his from an engineering motivation, and mine
from a medical motivation. We began working to-
gether right away. He would come to Washington,
DC, to meet me, and I went to South Carolina. After
a stint as Chair at AU, I was on a sabbatical at the
University of North Carolina Chapel Hill; Leonard
and I bought a house close to campus so that we
could host visitors. In particular, Steve Durham and
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I worked together quite a lot in that house and at
the Department of Statistics. Several other collab-
orators came down for extended periods, including
you (W.F.R.) and two of my doctoral students: Eloi
Kpamagen (now at Novavax) and Misrak Gezmu
(now at National Institutes of Health).
Rosenberger: The introduction of the random
walk rules coincided with the introduction of the
continual reassessment method (CRM; O’Quigley,
Pepe, and Fisher, 1990) in the Bayesian context. In
particular, you and Steve worked out the entire ex-
act distribution theory of a class of designs, while
others were relying on simulation. How does this
rank in terms of your contributions to statistics?
Flournoy: The random walk rules are extremely
practical and mathematically elegant, so it was a
lot of fun to develop the theory. They are the stan-
dard in many areas of science (e.g., American So-
ciety for Testing and Materials, 2010; Treutwein,
1995; National Institute of Environmental Health
Sciences, 2001). The key property that we discovered
was how to control the allocation coverage by intro-
ducing an appropriate bias (Durham and Flournoy,
1994). Steve was always thinking in terms of engi-
neering applications; I was always thinking in the
dose-response context. We did “reverse engineer-
ing,” in that we had a target allocation in mind, and
we found design parameters to facilitate this. The
designs are nonparametric in that allocation does
not depend on estimates of model parameters. They
are extraordinarily simple to illustrate and have ex-
act distribution theory that is unavailable for other,
more complicated designs.
Rosenberger: Some have lumped random walk
rules in the context of generic dose escalation de-
signs, such as the 3 + 3 design, that has no op-
timal properties. At the same time, Bayesian ap-
proaches, such as the CRM were becoming increas-
ingly well-known. Talk about the historic interplay
among these approaches.
Flournoy: Lloyd Fisher and John O’Quigley (from
the University of Leeds) were hired at the Can-
cer Center to replace me when I left for the NSF.
Lloyd and I laughed that it is not often one’s dis-
sertation advisor replaces his student! John was ini-
tially responsible for implementing a random walk
rule that I had designed in a pilot study for a bone
marrow clinical trial. He let them get away with a
simple dose escalation procedure, but he and Lloyd
got introduced to the subject at that time. They
immediately thought of doing a Bayesian alterna-
tive, and it was published in 1990 in Biometrics
(O’Quigley, Pepe and Fisher, 1990); the major ran-
dom walk paper appeared in Biometrics in 1997
(Durham, Flournoy and Rosenberger, 1997). Most
of the Bayesian literature was, by necessity, simula-
tion based, whereas Steve and I were busy obtaining
a complete workable probabilistic theory of the ran-
dom walk procedures.
There are a number of philosophical differences
among the approaches. Fedorov would call the CRM
a “best intention” approach, because it involves pre-
dicting a target dose and treating the next patient at
that dose, sequentially. Our approach is estimation-
motivated. The idea is to get allocations into a re-
gion of interest that allows us to efficiently estimate
the dose-response curve in that region.
There is also a short-memory and long-memory
distinction: allocation probabilities for the ran-
dom walk rule converge exponentially fast to their
asymptotic limits. Alternatively with best intention
designs (which to date are long-memory designs),
nonrepresentative early allocations can cause the de-
sign to converge to the wrong dose (see, e.g., Azriel,
Mandel and Rinott, 2011; Oron, Azriel and Hoff,
2011; Azriel, 2012). Such phenomena were observed
early on in the context of stochastic approxima-
tion designs (e.g., Lai and Robbins, 1982; Bozin and
Zarrop, 1991).
Adaptive optimal designs are promising long
memory designs, but they depend on parameter esti-
mates to get started. Random walk procedures that
target optimal design points provide good start-
up information with small sample sizes. Alterna-
tively, one can regularize the information matrix, a
“fix” that is often called “Bayesian designs” even
though no posterior distribution is obtained. True
Bayesian estimator updates coupled with dose al-
locations made in some stable optimal way, rather
than in a “best intention” way are also promising.
Rosenberger: What is the future of adaptive de-
signs? Do you think all clinical trials will eventually
be adaptive?
Flournoy: I think there is a great future for adap-
tive designs. I think experimentation will always in-
volve a series of trials; the question is how well one
utilizes information from one to the next. There is
a lot of value in relatively small but sequential tri-
als (see Flournoy, 2014), because these trials involve
many design features, including the grid size and
range on which you are operating. The best use of
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one experiment may be to tell you how you could
have better selected design characteristics; then you
can refine the estimate of the target of interest.
Some of my work has been on inference and es-
timation following adaptive designs (e.g., Rosen-
berger, Flournoy and Durham, 1997; Ivanova and
Flournoy, 2001; May and Flournoy, 2009; Lane, Yao
and Flournoy, 2014). One has to be careful doing
everything sequentially because some of the interim
changes may cause final estimates to lack normal-
ity. For example, in best-intention designs, the esti-
mate of a slope parameter can march off to infinity
for some common models. Also, even if an adaptive
dose-finding procedure has a fixed total sample size,
the sample sizes at each dose are random variables.
In up-and-down procedures, the proportion of sub-
jects allocated to each dose tends to a constant and
standard asymptotic normality results. But in many
other adaptive designs, proportions of subjects allo-
cated to each dose tend to a random variable. This
causes the conditional information matrix to be ran-
dom, even in the limit, in which case standard condi-
tions for asymptotic normality fail. These are many
interesting questions to be explored about adaptive
designs.
5. WOMEN IN STATISTICS
Rosenberger: Talk about the creation of Pathways
to the Future, its successes, and its legacy.
Flournoy: I went to the 1984 Annual IMS Meet-
ing in Lake Tahoe. At that meeting, there were five
women out of about 200 attendees. It became quite
clear to me that this was an important place for aca-
demic statisticians to meet and focus on academic
interests. In anticipation of the 1988 Fort Collins
IMS meeting, which was separate from the Joint
Statistical Meetings, I decided it would be great to
see more women there. So I bounced ideas off Mary
Ellen Bock (Purdue University) and Lynne Billard
(University of Georgia). Lynne agreed to take the
lead in organizing a workshop for women at the up-
coming IMS meeting. Lynne had the brilliant idea
of having Elizabeth Scott (University of California,
Berkeley) give the keynote lecture. At that time,
we were debating whether there was any gender in-
equity in academia, and we weren’t sure. I had never
experienced problems at UCLA or UW. However,
when I went to the NSF, Yash Mittal (the first fe-
male director of the probability program) and I saw
that there were almost no female grantees, and very
few were even applying for grants.
The evening presentation by Scott really hit us
very hard: she had tons of data and randomized
studies on gender inequity. Any questions about in-
equities in how women were recruited, judged and
valued were thrown out the window. Scott’s way
of handling this lecture was wonderful because she
went through all this horribly depressing data, but
she then turned around and finished the lecture by
telling us what we could do to protect ourselves. She
ended with two positive notes: that outcomes are
not predetermined, and one can take one’s career in
Fig. 6. Nancy, husband Leonard, and Lynne Billard at their home in Chapel Hill, NC, 1994.
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Fig. 7. Nancy, Ingram Olkin and Elizabeth Margosches (formerly with the Environmental Protection Agency) at the Cam-
panile at University of California, Berkeley, 2003.
one’s own hands. Lynne ran the workshop for the
next two decades, and she presented Scott’s lecture
with updated data every year. That lecture was the
last lecture Scott gave before she passed away. I re-
member well that there was a palpable sigh of relief
from Scott—that she could turn over her cause to
the next generation.
Rosenberger: How did you become NSF program
director? What was your experience with gender is-
sues there?
Flournoy: Ingram Olkin has long been a great
friend and mentor. He is the one who recommended
me to the NSF for the program director position. I
was the first female director in the statistics program
the same year that Yash Mittal was the first female
probability director. Some people had indicated to
the division director their fear I was going to give
all the grant money to biostatistics. I convinced him
that I could represent the entire statistics field.
One day I remember answering the phone and a
professor on the line yelled “I said I wanted to speak
to the director,” thinking a woman on the phone
must be a secretary.
We had a good travel budget and I went to as
many young women’s lectures as I could. I would go
up at the end of their talk and ask if they would be
interested in applying for a grant. By the time I left
NSF, the proportion of grant proposals from women
was proportional to their presence in the field. A
suggestion is such a small thing, and yet clearly im-
portant messages weren’t being transmitted to fe-
male faculty.
Rosenberger: Was discrimination subtle or not so
subtle when your career was developing?
Flournoy: Well, there was always sexist behavior
and many things that were said and done are consid-
ered inappropriate or even sexual misconduct today.
When I went on the job market for a fully academic
position I found that many men were incredulous.
Some would make outrageous comments directly to
me as if I were invisible (or a man). Men in my own
age category were often dismissive or oblivious to
my presence. Some of the older generation was very
helpful and supportive (I think of Shanti Gupta,
Purdue University; Norman Johnson, University of
North Carolina at Chapel Hill; Lucien LeCam, Uni-
versity of California, Berkeley; Ingram Olkin, Stan-
ford University; and Manny Parzen, Texas A&M
University). The younger generation just thought of
me as another senior person, so they were fine.
Rosenberger: What is your feeling about the role
of women in statistics today? I can say, from my
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perspective on 20 years of search committees, that
from a hiring perspective, we are thrilled to have
qualified women candidates and compete hard to
get them. And certainly policies on tenure to allow
maternity leave have vastly improved over the years,
as have the composition of committees and senior
administrators. Is there any work left to be done?
Flournoy: You can see improvement, but there are
still troubling facts: just try to find a woman in the
2013 JSM awards brochure, for instance. Women are
getting hired at proportional rates now, but awards,
tenure and advancement are areas where there much
is left to be done. See Lynne Billard’s new update of
Scott’s old data on the subject (Billard and Kafadar,
2015). That will depress you.
6. CONCLUSION
Rosenberger: You talked a little about your tran-
sition into a fully academic position. The latter part
of your career was spent at AU and University of
Missouri (MU), and considerable time as depart-
ment chair, and a mentor to many diverse students.
Talk about this.
Flournoy: AU was a great place for me when I
went there in 1988. I had left the Cancer Center
with a staff of 23, a budget of $700,000 and re-
sponsibilities that had become a burden when I be-
came convinced of the need for more nimble learning
strategies in dose-finding clinical trials. I had eight
doctoral students at AU, and all but two of them
developed mechanisms to control random walks and
urn models, and to provide mathematical descrip-
tions of their controlled behavior. One worked on
issues of inference following an adaptive design and
one worked on a problem in economics. I am proud
that four of these students are black and two are
women.
Unfortunately, a very destructive president came
to AU, and by 2000 it was clear that STEM gradu-
ate programs were going to be dismantled. AU had
one of the oldest statistics doctoral programs in the
country and it was sad to see it threatened by ig-
norance and arrogance. To remain in a department
with a doctoral program, I needed to move and this
led me to accept the chair at Missouri in 2002. When
I stepped down as chair in 2011, I had doubled the
number of tenure-track faculty and added five teach-
ing faculty positions. I increased the presence of the
department across campus through joint appoint-
ments and a targeted increase in service courses, and
Fig. 8. Nancy near Aasgard Pass in the Enchantment Lakes
Wilderness Area, Washington, where she was hiking with her
husband Leonard and her colleague Lori L. Thombs (Univer-
sity of Missouri) following the 2006 Joint Statistical Meetings
in Seattle.
I increased the prestige of the department nation-
ally, personally promoting our faculty and enabling
their participation in national and international ac-
tivities. More details can be found in a Chapter I
recently wrote on the history of statistics at MU
(Flournoy and Galen, 2012).
I have graduated seven doctoral students from
MU. We worked on adaptive and optimal designs;
we developed new models for specific, challenging
dose-response problems and we have illuminated the
effect of having dose allocations depend on the his-
tory of prior allocations and responses. My students
continue to bring me a great deal of pleasure.
Rosenberger: What are your hobbies and inter-
ests?
Flournoy: I love hiking. I am not happy with a
trip that takes less than four days. A four-day trip
has two days out and two days back—so one is never
very far from a road. After hiking for more than two
days, one must rely on one’s self much more com-
pletely. It is so peaceful. I gave up trying to hike
in the East and the Midwest United States. One
just can’t get far enough away from roads; and the
mountains aren’t high enough. I like trekking around
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timberline for a week or more where the views are
spectacular. I keep going back to Yosemite, Kings
Canyon and Sequoia National Forests. Nepal was
great, too. I try to get in one long hike each year.
In the meantime, I dance. I resumed ballet classes
while at AU; it is great mind-to-body exercise and
wonderful for strength and balance. Leonard and I
enjoy English country dance together. Throw in Pi-
lates and yoga and I am happy.
To survive a severe health challenge that had the
doctors stumped, I gained considerable knowledge
of alternative methods and became accomplished in
some. But that is another story.
Rosenberger: What’s next for Nancy Flournoy?
Flournoy: Well I have a lot of ideas. I’m really in-
terested in questions of inference following adaptive
designs. We have some examples in two stage designs
that maximum likelihood estimators are mixtures of
normals; some designs lead to estimators that are
normal with random variances. I think our prelim-
inary results are generalizable, but this remains to
be shown. I’m optimistic that tractable solutions to
seemingly intractable problems are at hand.
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